Patient Perspectives on Combination Therapy of a Once-weekly Oral Medication Plus Daily Medication for Lifestyle-related Chronic Diseases
نویسندگان
چکیده
Objective The current study investigated whether or not patients taking multiple daily oral medications for lifestyle-related chronic diseases would have positive perspectives on changing one of their medications to a once-weekly one. Methods A total of 1,071 Japanese outpatients participated in the current study. We performed a questionnaire-based survey and compared the current satisfaction with the ongoing daily oral treatment (current daily-only treatment) and an expected satisfaction with an imaginary oral treatment changing one of their daily oral medications to a once-weekly oral medication (imaginary daily-and-weekly treatment). Results Medications were taken for diabetes mellitus in 72% of the patients, for dyslipidemia in 54%, and for circulatory diseases, including hypertension, in 73%. Compared to their satisfaction with the current daily-only treatment, an expected satisfaction with the imaginary daily-and-weekly treatment was on average significantly attenuated (p<0.001, effect size d=0.49). The prevalence of a higher satisfaction score for the imaginary daily-and-weekly treatment versus the current daily-only treatment was 30% in the overall population. The prevalence was 59%, 40%, 29%, 14%, and 8% in the 1st, 2nd, 3rd, 4th, and 5th quintile of the satisfaction score with the current daily-only treatment (p<0.001 for trend). Conclusion Treatment satisfaction would be on average attenuated if one of the multiple daily oral medications was changed to a once-weekly one. Improvement in the satisfaction was less expected in the subgroup that was more satisfied with the current daily-only treatment.
منابع مشابه
Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol
Medication adherence among patients with chronic diseases, such as COPD, may be suboptimal, and many factors contribute to this poor adherence. One major factor is the frequency of medication dosing. Once-daily dosing has been shown to be an important variable in medication adherence in chronic diseases, such as COPD. New inhalers that only require once-daily dosing are becoming more widely ava...
متن کاملPeginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial.
Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in ...
متن کاملThe Efficacy of Cognitive Behavioral Group-Therapy Alone and plus Family Psycho-Education on the Treatment of Major Depression Disorder Symptoms in Females
Background & Aims: Major depression is one of the common psychiatric disorders imposing negative effects on patients and their families. There are several treatment methods for depression. The purpose of the present study was to determine the effect of combination of cognitive behavioral group therapy, family psycho-education and medication versus medication alone on the improvement of major...
متن کاملA Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus
INTRODUCTION Previous research has demonstrated a correlation among patient preferences, dosing burden, and medication nonadherence, a well-recognized challenge in type 2 diabetes mellitus (T2DM). The objective of this study was to elicit preferences for alternative dosing regimens for oral antihyperglycemic therapies among patients with T2DM and to quantify differences in dosing preferences am...
متن کاملRole of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device (Ultibro, Breezhaler), often called QVA149, was first approved in 2013 in Japan and Europe. As of November 2014, more than 40 countries had approved this medication except for the USA. This is the first dual bronchodilator in one device. Now, the Breezhaler is the only device that can provi...
متن کامل